Zocdoc launches AI phone assistant 'Zo' for scheduling medical appointments, with CEO Oliver Kharraz saying it's a natural ...

Icon and Medpace report high R&D project cancellations; Icon sees $659M in Q1 cancellations, cuts guidance; Medpace notes ...

Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine ...

When Siren Biotechnology CEO Nicole Paulk learned last month that top FDA official Peter Marks had resigned, she began ...

Arvinas, along with its partner Pfizer, cancelled plans for a Phase 3 trial combining its PROTAC vepdegestrant with its CDK4 ...

Moderna is expanding a cost control program as it seeks to break even in the coming years, despite challenges for vaccine ...

Biogen reports Leqembi Alzheimer's drug sales reached $96M in Q1, up from $19M last year, with $52M from US market. Eisai ...

Amicus pays Dimerix $30M upfront for US rights to DMX-200, a late-stage FSGS therapy, with potential milestone payments of ...

Eli Lilly posted $12.73 billion in revenue in the first quarter, a 45% jump from the prior year, matching the percentage ...

Stately Bio has raised a $12 million seed round led by AIX Ventures to advance machine learning techniques that recognize ...

Artios Pharma, a startup developing drugs that weaken a tumor’s ability to maintain its DNA, announced positive results in a ...

A tribunal within the US Patent and Trademark Office invalidated several claims of a patent held by AbbVie’s Pharmacyclics, ...